[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2171419T3 - Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina. - Google Patents

Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina.

Info

Publication number
ES2171419T3
ES2171419T3 ES93923110T ES93923110T ES2171419T3 ES 2171419 T3 ES2171419 T3 ES 2171419T3 ES 93923110 T ES93923110 T ES 93923110T ES 93923110 T ES93923110 T ES 93923110T ES 2171419 T3 ES2171419 T3 ES 2171419T3
Authority
ES
Spain
Prior art keywords
citrochrome
acridine
metabolism
inhibitors
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923110T
Other languages
English (en)
Inventor
Thomas F Woolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/943,323 external-priority patent/US5422350A/en
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2171419T3 publication Critical patent/ES2171419T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

SE DESCRIBE UN METODO DE INHIBICION DEL METABOLISMO ENZIMATICO DE ACRIDINAS SUSTITUIDA POR NITROGENO QUE COMPRENDE LA ADMINISTRACION SIMULTANEA CON LA ACRIDINA DE UNA CANTIDAD EFECTIVA INHIBIDORA DE LA OXIDASA DE UN INHIBIDOR P450 1A2. LA OXIDASA CUYA ACTIVIDAD ESTA INDUCIDA POR BETA-NAFTAFLAVONE, 3-METILOCOLANTRENO, AROCLORO, 2,3,7,8-TETRACLORODIBENZO-P-DIOXINA E ISOSAFROL. EL INHIBIDOR DE LA OXIDASA PUEDE SER UNA NAFTIRIDINA, UNA XANTINA, UN FENOXIAMINOALCANO, UNA CARBAMOILO IMIDAZOLA, UNA GUANIDINA HETEROCICLICA, UNA QUINOLINA O UN ETER OXIMA TRIFLUOROMETILO.
ES93923110T 1992-09-10 1993-09-08 Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina. Expired - Lifetime ES2171419T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/943,323 US5422350A (en) 1992-09-10 1992-09-10 Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US08/100,917 US5466696A (en) 1992-09-10 1993-08-09 Tacrine and cytochrome P450 oxidase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
ES2171419T3 true ES2171419T3 (es) 2002-09-16

Family

ID=26797688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923110T Expired - Lifetime ES2171419T3 (es) 1992-09-10 1993-09-08 Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina.

Country Status (18)

Country Link
US (1) US5466696A (es)
EP (1) EP0659082B1 (es)
JP (1) JPH08501105A (es)
KR (1) KR950703339A (es)
AT (1) ATE212845T1 (es)
AU (1) AU669586B2 (es)
CA (1) CA2141425A1 (es)
CZ (1) CZ48095A3 (es)
DE (1) DE69331546T2 (es)
DK (1) DK0659082T3 (es)
ES (1) ES2171419T3 (es)
FI (1) FI951024A0 (es)
HU (1) HU217845B (es)
NO (1) NO307955B1 (es)
NZ (1) NZ256940A (es)
PT (1) PT659082E (es)
SK (1) SK26495A3 (es)
WO (1) WO1994005296A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2285948A1 (en) * 1997-04-28 1998-11-05 The University Of British Columbia Method and composition for modulating amyloidosis
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU779900B2 (en) * 1999-07-22 2005-02-17 Organogenesis Inc. In vivo induction for enhanced function of isolated hepatocytes
JP4355212B2 (ja) * 2001-12-21 2009-10-28 オーガノジェネシス インコーポレーテッド 細胞培養及び臓器補助用の可変容量チャンバ
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US7583551B2 (en) 2004-03-10 2009-09-01 Micron Technology, Inc. Power management control and controlling memory refresh operations
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
WO2008153722A1 (en) * 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
DE1643240A1 (de) * 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
SU429813A1 (ru) * 1971-08-20 1974-05-30 Способ лечения туберкулеза легких
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
SU789112A1 (ru) * 1979-04-12 1980-12-23 Научно-исследовательский институт экспериментальной и клинической медицины Способ лечени экстрасистолической аритмии у детей
SU827081A1 (ru) * 1979-06-05 1981-05-07 Донецкий Медицинский Институт Им.M.Горького Способ лечени вазомоторных головныхбОлЕй
GB2091249A (en) * 1980-12-23 1982-07-28 Fordonal Sa Xanthine derivatives
SU1049065A1 (ru) * 1981-01-09 1983-10-23 Andronova Liliya Z Способ лечени заикани
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
SU1156700A1 (ru) * 1982-01-19 1985-05-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени неврозов
SU1210789A1 (ru) * 1983-07-21 1986-02-15 Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова Способ диагностики функционального нарушени желудочной секреции
SU1196002A1 (ru) * 1984-06-28 1985-12-07 Запорожский государственный институт усовершенствования врачей им.М.Горького Способ лечени хронического сальпингоофорита
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4695573A (en) * 1984-10-25 1987-09-22 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4754050A (en) * 1984-10-25 1988-06-28 Hoechst-Roussel Pharmaceuticals, Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4835275A (en) * 1984-10-25 1989-05-30 Hoechst-Roussel Pharmaceuticals, Inc. Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds
EP0179383B1 (en) * 1984-10-25 1991-05-29 Hoechst-Roussel Pharmaceuticals Incorporated 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
SU1537252A1 (ru) * 1985-03-28 1990-01-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени парестезий полости рта
SU1416125A1 (ru) * 1986-02-21 1988-08-15 Одесский Научно-Исследовательский Институт Курортологии Способ лечени заболеваний суставов
SU1389050A1 (ru) * 1986-07-28 1990-08-30 Niiex Meditsiny An Sssr Cпocoб лeчehия aлkoгoлизma
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
FI90417C (fi) * 1988-11-16 1994-02-10 Hoechst Marion Roussel Inc Menetelmä terapeuttisesti aktiivisten hydroksi-1,2,3,4-tetrahydroaminoakridiinien valmistamiseksi
GB8827704D0 (en) * 1988-11-28 1988-12-29 Fujisawa Pharmaceutical Co New acridine derivatives & processes for their production
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine

Also Published As

Publication number Publication date
DE69331546T2 (de) 2002-10-31
DK0659082T3 (da) 2002-06-17
US5466696A (en) 1995-11-14
KR950703339A (ko) 1995-09-20
DE69331546D1 (de) 2002-03-21
WO1994005296A2 (en) 1994-03-17
SK26495A3 (en) 1996-05-08
AU5290593A (en) 1994-03-29
FI951024A (fi) 1995-03-06
WO1994005296A3 (en) 1994-04-28
JPH08501105A (ja) 1996-02-06
AU669586B2 (en) 1996-06-13
FI951024A0 (fi) 1995-03-06
EP0659082A1 (en) 1995-06-28
CZ48095A3 (en) 1995-12-13
PT659082E (pt) 2002-07-31
HUT70979A (en) 1995-11-28
HU217845B (hu) 2000-04-28
NO950909L (no) 1995-03-09
NZ256940A (en) 1996-03-26
NO307955B1 (no) 2000-06-26
ATE212845T1 (de) 2002-02-15
EP0659082B1 (en) 2002-02-06
HU9500704D0 (en) 1995-04-28
NO950909D0 (no) 1995-03-09
CA2141425A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n&#39;-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
NO931766L (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
ATE299890T1 (de) Inhibitoren von gamma-secretase
ES2171419T3 (es) Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina.
NO953370L (no) Anvendelse av riluzol ved behandling av neuro-AIDS
DE59511017D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
ES2146249T3 (es) Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
ATE149840T1 (de) Behandlung von leberkrebs
PT900082E (pt) Utilizacao de piridilpiperazina e pirimidilpiperazina para o fabrico de um medicamento para o tratamento de perturbacoes de toxicomania
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
NO995539D0 (no) Anvendelse av hepariner med lav molekylvekt for prevensjon og terapi av cerebrale ödemer
BR9810335A (pt) Uso de inibidores de fosfolambano para aumentar o fluxo coronário
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
DE69428276D1 (de) Insulinähnlicher wachstumfaktor ii als antitumormittel
ATE145135T1 (de) Verwendung von riluzol zum schutz gegen strahlenschäden
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
IT1263041B (it) Derivati di s,s&#39;-bis(carbossammidofenil)-disolfuro ad attivita&#39; cardiovascolare

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 659082

Country of ref document: ES